|Other names||4-Hydroxytamoxifen; 4-OHT; 4-HT; OHTAM|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||387.5139 g/mol g·mol−1|
|3D model (JSmol)|
Afimoxifene is a selective estrogen receptor modulator (SERM) of the triphenylethylene group and the major active metabolite of tamoxifen. The drug is under development under the tentative brand name TamoGel as a topical gel for the treatment of hyperplasia of the breast. It has completed a phase II clinical trial for cyclical mastalgia, but further studies are required before afimoxifene can be approved for this indication and marketed.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|